Sirio secures TGA GMP certification to support strategic growth in Australia

The Ma’anshan site approval covers pastilles, oral liquids, and powders

Alembic gets FDA final approval for Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL Single-Dose Prefilled Syringe

Dabur's NewU signs Unicommerce to power its omnichannel operations

Schneider Electric and Apollo Hospitals collaborate for energy-efficient healthcare solutions

Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025

Botanic Healthcare launches Rs. 25 crore liposomal manufacturing facility in Hyderabad

New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production

Evonik and Ethris partner to expand offerings for nucleic acid delivery

Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support

Novartis to acquire Tourmaline Bio for $1.4 billion

Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease

Ichnos Glenmark Innovation receives upfront payment of $700 million from AbbVie

The payment is in accordance with the agreed contractual terms

MRM Health raises €55 million Series B to advance microbiome-based biotherapeutic product pipeline

Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval

FDA grants Fast Track Designation for Teva’s Emrusolmin

Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development